Experimental
PE-22-28
The prediction game
Call it: rising or fading?
Where does PE-22-28 stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: E (thin evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 4.9/10
PE-22-28 sits in caution because it pairs one of the cleaner mechanisms in the grey-market peptide world with a completely empty human file. The TREK-1 to depression link is real and well-characterized, the rodent antidepressant and neurogenesis data is genuine, and the speed of onset is the kind of thing that makes the whole class exciting, per Mazella 2010 and Djillani 2017. But there are zero human trials, the dose response is biphasic in a way that can reverse the effect, and TREK-1 is expressed in the heart, pancreas, and gut, so a systemic blocker carries uncharacterized off-target risk, per Hivelin 2016. Promising mechanism, no human proof, grey-market. ✅ Best for: Researchers and very experienced self-experimenters who fully understand that this is preclinical and act accordingly. People who grasp the biphasic-dosing trap and would not assume a higher dose is better. Anyone tracking the TREK-1 antidepressant story for its scientific interest rather than treating it as a ready tool. Users who accept that grey-market sourcing means unverified purity, sterility, and identity on top of an already unvalidated compound. ❌ Avoid if: You want an evidence-backed mood or antidepressant tool, since none of the human proof exists, and options like Semax at least have human use behind them. You have any cardiovascular condition, diabetes or blood-sugar issues, or gut conditions, since TREK-1 sits in all those tissues and human safety is unknown. You would be tempted to push the dose upward, since that can flip the effect. You cannot verify source quality, since contamination risk may exceed the intrinsic pharmacological risk. You expect a settled protocol, since there is no validated human dose.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 0.0%
- BioHarmony Score
- 4.9/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.